S&P Futures
4,167.25 -24.25 (-0.58%) Dow Futures
34,085.00 -12.00 (-0.04%) Nasdaq Futures
12,642.00 -204.75 (-1.59%) Russell 2000 Futures
2,005.70 -2.20 (-0.11%) Crude Oil
75.86 -0.02 (-0.03%) Gold
1,930.60 -0.20 (-0.01%)
Surface Oncology, Inc. (SURF)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.9700 |
| Open | 0.9901 |
| Bid | 0.9751 x 2200 |
| Ask | 1.0100 x 1200 |
| Day's Range | 0.9511 - 1.0100 |
| 52 Week Range | 0.6020 - 3.8100 |
| Volume | |
| Avg. Volume | 312,433 |
| Market Cap | 58.817M |
| Beta (5Y Monthly) | 1.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2330 |
| Earnings Date | Feb 28, 2023 - Mar 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.40 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SURF
Related Research
- Surface Oncology, Inc.Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.RatingFair ValueEconomic Moat11 hours agoMorningstar
- GlobeNewswire
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Days conference in New York City on Thursday, February 9, 2023, at 1:35 p.m. ET. A live audio webcast of the session may be accessed by visiting the Events page
- Simply Wall St.
Shareholders in Surface Oncology (NASDAQ:SURF) are in the red if they invested a year ago
Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders should be happy to see the share price up 25% in the last month...
- Zacks
TG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
